Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A2 | O94788 | 3/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5429211 | 0.88 | ALDH1A2 (0.41) | ALDH1A2ALDH1A3PTGS2KDM1A | |
| SCHEMBL5441947 | 0.87 | ALDH1A2 (0.41) | ALDH1A2ALDH1A3ALDH1A1KDM1A | |
| SCHEMBL5429596 | 0.87 | ALDH1A2 (0.38) | ALDH1A2ALDH1A3EPHX1PTGS2KDM1A | |
| SCHEMBL5426588 | 0.85 | ALDH1A2 (0.43) | ALDH1A2ALDH1A3ALDH1A1KDM1A | |
| SCHEMBL5438338 | 0.85 | KDM1A (0.39) | ALDH1A2ALDH1A3KDM1AKMT2A | |
| SCHEMBL5437168 | 0.84 | PTGS2 (0.39) | ALDH1A2ALDH1A3ALDH1A1PTGS2KDM1A | |
| SCHEMBL5435811 | 0.83 | ALDH1A2 (0.40) | ALDH1A2ALDH1A3KDM1A | |
| SCHEMBL5432508 | 0.83 | KDM1A (0.36) | ALDH1A2ALDH1A3ALDH1A1KDM1A | |
| SCHEMBL5434800 | 0.78 | ALDH1A2 (0.40) | ALDH1A2ALDH1A3ALDH1A1KDM1A | |
| SCHEMBL5440520 | 0.78 | ALDH1A2 (0.42) | ALDH1A2ALDH1A3ALDH1A1PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | claimed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | ALDH1A2 1259/4885ALDH1A3 1534/4885ALDH1A1 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.